LinkedIn·Thursday, 6 August 2026·20d ago
Yesterday the FDA approved #mFLUSIVA: the first flu vaccine built on #mRNA. A milestone — and not just for Moderna. RNA has now stepped out…
Ziphius
4,707 followers
Yesterday the FDA approved #mFLUSIVA: the first flu vaccine built on #mRNA.
A milestone — and not just for Moderna. RNA has now stepped out of the "pandemic exception" category, onto an ordinary regulatory path: file, data, decision.
At Ziphius we build on exactly those foundations — with a different engine.
Conventional #mRNA delivers the instruction once: the cell reads it, produces the antigen, and the signal fades. Our self-amplifying RNA (#saRNA) brings the replication machinery along. The RNA copies itself inside the cell, so the signal holds longer and stronger from a far smaller starting dose.
Why our #saRNA matters:
Dose — a lower dose aimed at fewer side effects.
Duration — a persisting antigen signal, aimed at addressing unmet needs.
Breadth — the same platform, adaptable across targets.
Congratulations to the team at Moderna. The bar just moved up, and that is good news.
At Ziphius, we make #RNA work harder.
#saRNA #RNA #vaccines #biotech #Ziphius
Cross-referenced
Related on the wire
A Historic Moment for #mRNA Medicine For the first time, an individualized mRNA-based cancer treatment has demonstrated a clear benefit…
In deze podcastaflevering deelt onze CEO Chris Cardon inzichten uit zijn ondernemersparcours: van zijn achtergrond als apotheker, over de…
Today, a total solar eclipse is visible across #Belgium, as the moon moves precisely in front of the sun. At Ziphius, we use #genetics to…
🎂🧬 RNA Day at Ziphius #AUG isn't just the abbreviation for August. It's also the #RNA start codon that tells cells where to begin making…
What happens behind the scenes at Ziphius? What started a few weeks ago with a visit to our site in Zwijnaarde is now a finished report…